Article thumbnail
Location of Repository

Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety

By Helen Y How and Baha M Sibai

Abstract

Preterm birth is the leading cause of neonatal mortality and morbidity and long-term disability of non-anomalous infants. Previous studies have identified a prior early spontaneous preterm birth as the risk factor with the highest predictive value for recurrence. Two recent double blind randomized placebo controlled trials reported lower preterm birth rate with the use of either intramuscular 17 alpha-hydroxyprogesterone caproate (IM 17OHP-C) or intravaginal micronized progesterone suppositories in women at risk for preterm delivery. However, it is still unclear which high-risk women would truly benefit from this treatment in a general clinical setting and whether socio-cultural, racial and genetic differences play a role in patient’s response to supplemental progesterone. In addition the patient’s acceptance of such recommendation is also in question. More research is still required on identification of at risk group, the optimal gestational age at initiation, mode of administration, dose of progesterone and long-term safety

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2697509
Provided by: PubMed Central

Suggested articles

Citations

  1. (1994). A new method using vaginal ultrasound and transfundal pressure to evaluate the asymptomatic incompetent cervix. Obstet Gynecol.
  2. A randomized controlled trial of cervical cerclage in women at high risk for preterm delivery.
  3. (1989). Acculturation and low birthweight among Latinos in the Hipanic HANES.
  4. Acculturation and marijuana and cocaine use:
  5. (2003). American College of Obstetricians and Gynecologists. ACOG committee opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol.
  6. Annual summary of vital statistics-1996.
  7. (1994). Bacterial vaginosis is associated with prematurity and vaginal fl uid mucinase and sialidase: Results of controlled trial of clindamycin cream.
  8. (1977). Birth defects and Drugs in Pregnancy.
  9. (2001). Births: preliminary data for 2000. Natl Vital Stat Rep.
  10. Causes of low birth weight births in public and private patients.
  11. (1993). Changes in 17 B, 20-alpha-hydroxysteroid dehydrogenase activity supporting an increase in the estrogen/ progesterone ratio of human fetal membranes at parturition.
  12. Changing paternity and the risk of preterm delivery in the subsequent pregnancies.
  13. (1993). Collaborative Group on Preterm Birth Prevention. Multicenter randomized controlled trial of a preterm birth prevention program.
  14. (1989). Controlled trial of a preterm labor detection program: effi cacy and costs. Obstet Gynecol.
  15. (1993). Correlations of birth weight and gestational age across generations. Ann Hum Biol.
  16. (1984). Daily hormonal changes in the maternal, fetal and amniotic fl uid compartments before parturition in a primate species. J Clin Endocrinol Metab.
  17. Delayed childbearing and its impact on population rate changes in lower birth weight, multiple birth, and preterm delivery.
  18. (1978). Demonstration that progesterone “blocks” uterine activity in the ewe in vivo by a direct action on the myometrium. J Reprod Fertil.
  19. (1970). Double blind study of an agent to prevent pre-term delivery among women at increased risk.
  20. (1997). Effect of alteration of maternal plasma progesterone concentration on fetal behavioural state during late gestation.
  21. (1995). Effect of United States residence on birth outcomes among Mexican immigrants: An exploratory study.
  22. Effects on pregnancy outcome of changing partner between fi rst two births: prospective population study.
  23. Efficacy of 17α-hydroxyprogesterone caproate in the prevention of premature labor.
  24. (1982). Elective cervical suture of twin pregnancies diagnosed ultrasonically in the fi rst trimester following induced ovulation. Gynecol Obstet Investig.
  25. Endocrinology of human parturition: a review.
  26. (1991). Epidemiologic characteristics of preterm delivery: Etiologic heterogeneity.
  27. (1988). Epidemiology of birth before 28 weeks of gestation. Brit Med Bull.
  28. (1995). Epidemiology of preterm delivery in two birth cohorts with an interval of 20 years.
  29. (1991). Etiologies of preterm birth in an indigent population: Is prevention a logical expectation? Obstet Gynecol.
  30. Factors associated with spontaneous preterm birth.
  31. Familial trend in low birthweight.
  32. Familial trends in low birth weigh.
  33. FDA issues NDA 21-945. Proposed Indication. “Gestiva is indicated for the prevention of preterm birth
  34. (2007). for NICHD MFMU Network. Follow-up of children exposed to 17 Aalpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol.
  35. For NICHD MFMU network. Mid-Trimester endovaginal sonography in women at high risk for spontaneous preterm birth.
  36. for the Fetal Medicine Foundation, Second Trimester Screening Group. Progesterone and the Risk of Preterm Birth Among Women with a Short Cervix.
  37. for the research group in obstetrics and gynecology. Cervical length and funneling at 22 and 27 weeks to predict spontaneous birth before 32 weeks in twin pregnancies: A French prospective multicenter study.
  38. (1987). Genetic heterogeneity of prematurity and intrauterine growth retardation: Clues from the old order Amish. Am J Obstet Gynecol.
  39. (1991). Gestational duration and birthweight in white, black and mixed-race babies. Paediatr Perinat Epidemiol.
  40. Habitual abortion: a controlled clinical study of pregestational therapy.
  41. (1993). Hormonal modulation of uterine activity during primate parturition. Semin Reprod Endocrinol.
  42. (1998). IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-Ra and IL-1beta genes.
  43. (1998). Illicit drug use among Mexicans and Mexican Americans in California: the effects of gender and acculturation.
  44. (1997). Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial.
  45. (2007). Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogeterone caproate.
  46. (1984). Increasing saliva (free) oestriol to progesterone ration in late pregnancy: a role for oestriol in initiating spontaneous labor in man? Br Med J Clin Res Ed.
  47. (1980). Inefficacy of 17α−hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol.
  48. (1997). Inhibition and augmentation of progesterone production during pregnancy: effects of parturition and rhesus monkeys.
  49. (1994). Initiation of parturition.
  50. (1985). Intraumuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function. Acta Obstet Gynecol Scand.
  51. (1991). Is Preterm delivery genetically determined? Paediatr Perinat Epidemiol.
  52. Living with the past: evolution, development and patterns of disease.
  53. (1999). Low birth weight and prematurity in relation to paternal factors: a study of recurrence.
  54. (2003). Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online.
  55. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis.
  56. (1991). Mifepristone (RU486) alone or in combination with prostaglandin analogue for termination of early pregnancy: A review. Fertil Steril.
  57. (1998). Monitoring women at risk for preterm labor.
  58. Multicentered controlled trial of cervical cerclage in women at moderate risk of preterm delivery.
  59. Natural progesterone: what role in women’s health care? Women’s Health Primary Care.
  60. NICHD MFMU Network. A trial of 17-Alpha-hydorxyprogesterone Caproate to prevent prematurity in Twins.
  61. NICHD MFMU Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
  62. of Dimes Birth Defects Foundation. Available at:
  63. (2006). of the National Academies. Preterm Birth: Causes, Consequences, and Prevention. Washington DC;
  64. Perinatal drug use among immigrant and native-born latinas. Subst Use Misuse. 1997;32:43–62.Therapeutics and Clinical Risk Management 2009:5 63 Progesterone for preventing preterm birth
  65. (2004). Pharmacokinetics of natural progesterone vaginal suppository. Gynecol Obstet Invest.
  66. Plasma estrone, estradiol, estriol, progesterone, and 17-hydroxyprogseterone in human pregnancy. I. Normal pregnancy.
  67. (2001). Practice bulletin ACOG: clinical management guidelines for obstetrician gynecologist #31-assessment of risk factors for preterm birth. Obstet Gynecol.
  68. (1993). Prediction and early diagnosis of preterm labor: A critical review. Obstet Gynecol Surv.
  69. (1994). Prematurity prevention programs: An analysis of successes and failures.
  70. (1989). Preterm birth prevention: evaluation of a prospective controlled randomized trial.
  71. (1992). Preterm delivery and low birth weight among frist-born infants of black and white college graduates.
  72. (1996). Preterm delivery and perinatal death among black and white infants in a Chicago-area perinatal registry. Obstet Gynecol.
  73. (2001). Preterm delivery: a public health perspective. Paediatr Perinat Ep.
  74. (1999). Preterm labor. In:
  75. (1994). Prevalence of low birth weight among Hispanic infants with United States-born and foreign-born mothers: The effect of urban poverty.
  76. (1998). Prevention of premature birth.
  77. (1985). Prevention of premature labor by 17 alphahydroxyprogesterone caproate.
  78. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
  79. Progesterone … what is it? Accessed
  80. (1990). Progesterone administration in pregnancy may prevent preterm delivery.
  81. (2005). Progesterone and pregnancy. Curr Opin Obstet Gynecol.
  82. Progesterone binding to serum proteins.
  83. Progesterone for prevention of recurrent preterm birth: Impact of gestational age at previous delivery.
  84. (2000). Progesterone for the luteal support of assisted reproductive technologies: clinical options. Human Reprod.
  85. Progesterone inhibition in mid-trimester termination of pregnancy: Physiological and clinical effects.
  86. (2007). Progesterone vaginal gel for the reduction of recurrent preterm birth: Primary results from a randomized, double blind, placebo controlled trial. Ultrasound Obstet Gynecol.
  87. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous Preterm birth in women at increased risk: A randomized placebo-controlled double-blind study.
  88. (2007). Prophylaxis with 17 Alphahydroxyprogesterone Caproate for Prevention of Recurrent Preterm Delivery: Does Gestational Age at Initiation of Treatment Matter? Am J Obstet Gynecol.
  89. Rates of preterm delivery among black women and white women in the United States over two decades: an age-period-cohort analysis.
  90. (1998). Relation of traditional risk factors to intrauterine growth retardation among United States-born and foreign-born Mexican Americans in Chicago. Ethnicity Dis.
  91. (1997). scientifi c and ethical aspects of fetal and neonatal care at extreme preterm periods of gestation.
  92. Second-generation consequences of small for dates births.
  93. (1998). Social variation in size at birth and preterm delivery in the Czech Republic and Sweden, 1989–1991. Paediatr Perinat Ep.
  94. (1997). Suppression of arousal by progesterone in fetal sheep. Reprod Fertil Dev.
  95. (1980). System for predicting spontaneous preterm birth. Obstet Gynecol.
  96. (1985). Taffel SM. Childbearing characteristics of US -and foreign-born hispanic mothers. Public Health Rep.
  97. (1977). The “see-saw” theory of parturition. In:
  98. The effect of 17 alphahydroxyprogestrone caproate on pregnancy outcome in an active-duty military population.
  99. (1994). The initiation and inhibition of labour-toward a molecular understanding. Semin Reprod Endocrinol.
  100. (1997). The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol.
  101. (1996). The length of the cervix and the risk of spontaneous premature delivery.
  102. (1975). The mechanisms by with foetal cortiosol controls the onset of parturition in the sheep. Biochem Soc Trans.
  103. (1999). The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome.
  104. (1998). The preterm prediction study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births.
  105. (1985). The repetition of spontaneous preterm labor.
  106. (1985). The repetition of spontaneous preterm labour.
  107. (1997). The risk of preterm birth across generations. Obstet Gynecol.
  108. The tendency to repeat gestational age and birth weight in successive births.
  109. Tocolytic treatment for the management of preterm labor: a review of the evidence.
  110. Treatment of threatened premature labor with large does of progesterone.
  111. (2003). Trends in multiple births conceived using assisted reproductive technology, united states, 1997–2000 Pediatrics.
  112. Unravelling the genetics of complex disorders of reproduction.
  113. Vaginal fetal fi bronectin measurements from 8 to 22 weeks’ gestation and subsequent spontaneous preterm birth.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.